MedTrace Logo

A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504

NCT07770217 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-08-18

No results posted yet for this study

Summary

This is a single-center, open-label, fixed-sequence, self-controlled Phase I clinical study with a planned enrollment of approximately 18 healthy participants.

Conditions

  • Healthy Participants

Interventions

DRUG

HS-10504

Participants will receive a single oral dose of 400 mg HS-10504 tablets on study days D1 and D17, respectively

DRUG

Rifampin

articipants will receive Rifampin capsules 600 mg orally once daily on an empty stomach from Day 10 to Day 24 for 15 consecutive days

Sponsors & Collaborators

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-02
Primary Completion
2026-09-10
Completion
2026-11-29
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07770217 on ClinicalTrials.gov